Renal osteodystrophy  by Coburn, Principal Discussant: Jack W.
Kidney International, Vol. 17 (1980), pp. 677-693
NEPHROLOGY FORUM
Renal osteodystrophy
Principal Discussant . JACK W. COBURN
Nephrology Section, VA Wadsworth Medical Center and UCLA School of Medicine, Los Angeles, California
Case presentation
A 66-year-old man with chronic renal failure was admitted to
the Wadsworth VA Medical Center for evaluation of bone pain
and severe muscle weakness. Approximately 3 years prior to ad-
mission, an elevated serum creatinine of 6 mg/dl was first detect-
ed. Evaluation at that time included an intravenous pyelogram,
which revealed bilateral scarred and shrunken kidneys without
evidence of obstruction. The 24-hour unne protein excretion was
1.5 grams; serum calcium, 8.6 mg/dl; serum phosphorus, 6.5 mgI
dl; and alkaline phosphatase, 90 IU. One urine culture was sterile
and the anti-nuclear antibody was negative.
Renal failure progressed and 18 months prior to admission the
patient was started on maintenance hemodialysis. He did well on
dialysis except for the development of bone pain and severe
muscle weakness.
Medications at the time of admission included: digoxin, 0.125
mg every other day; Dilantin®, 300 mg daily; aluminum hydrox-
ide, 3 tabs three times daily. Physical examination revealed:
blood pressure 140/70; pulse 80/mm; respiration, 12/mm; temper-
ature, 37.5° C. A grade 1/VI systolic murmur was heard at the left
sternal border. A functioning arteriovenous fistula was present in
the right arm. The remainder of the physical examination was
unremarkable. Laboratory data revealed the following: hemato-
crit, 34%; WBC, 7500/mm3; BUN, 85 mg/dl; creatinine, 10.7 mgI
dl; serum calcium, 10.2 mg/dl; and serum phosphorus, 3.6 mgldl.
The serum magnesium was 2.9 mEq; serum sodium, 138 mEq;
serum potassium, 5.4 mEq; serum chloride, 97 mEq; and serum
bicarbonate 18 mEq per liter. The alkaline phosphatase was 217
units; serum albumin, 3.8 g/dl; total protein 8 g/dl; serum immu-
noreactive parathyroid hormone (iPTH), 1.55 ng/ml (normal less
than 0.4 nglml); and 25-hydroxycholecalciferol, 19 nglml (normal
= 12-60 ng/mI). Roentgenograms revealed subperiosteal resorp-
tion of both hands and distal clavicles. One day after admission,
an ileal crest bone biopsy was performed.
The biopsy showed increased resorbing and forming surface,
increased osteoid (18.3% unmineralized bone), and severe mar-
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row-space fibrosis (4.8%) (Fig. 1). These findings were inter-
preted as consistent with osteomalacia and osteitis fibrosa with
osteitis fibrosis predominating.
Treatment with 1 ,25-dihydroxycholecalciferol [1 ,25(OH)2D3]
was initiated at a dose of 1 gIday, and aluminum hydroxide was
continued at a dose of 3 tabs three times daily. Within one month
of initiation of treatment, the patient's muscle weakness im-
proved dramatically and his bone pain diminished. By two
months, when the serum calcium was 10.0 mg/dl and the serum
phosphorus was 3.0 mg/dl, the alkaline phosphatase had declined
slightly to 180 units and the PTH had fallen to 0.95 ng/ml. By 6
months, the serum alkaline phosphatase had fallen further to 105
units, serum calcium was then 12 mgldl, and serum phosphorus
was 7 mgldl. The serum calcium continued to rise to 13.2 mgldl
and the I ,25(OH)2D3 was discontinued. One month later a repeat
bone biopsy was performed. Serum calcium at the time of biopsy
was 10.4 mg/dl; serum phosphorus, 4.4 mg/dl; alkaline phospha-
tase, 95 units; and serum PTH 0.22 nglml. The patient's clinical
course is shown in Fig. 2.
The repeat biopsy showed an increase in the forming surface, a
slight decrease in the resorbing surface, and a marked reduction
in marrow-space fibrosis (1%) (Fig. 3). Percentage mineralization
had improved to 95.1%.
Discussion
DR. JACK W. COBURN (Chief, Nephrology Sec-
tion, VA Wadsworth Medical Center, and Pro-
fessor of Medicine, UCLA School of Medicine, Los
Angeles, California): This patient presents a num-
ber of features characteristic of symptomatic renal
osteodystrophy. I will use this term in a broad,
generic sense to include all skeletal abnormalities
in uremia, i.e., osteitis fibrosa, osteomalacia, osteo-
sclerosis, and growth failure in children. On the
basis of the radiographic findings of increased
subperiosteal resorption and elevated levels of
serum immunoreactive parathyroid hormone (iPTH),
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Fig. 1. Pretreatment bone biopsy showing extensive marrowfi-
brosis. There is an increase in unmineralized osteoid (dark red)
underlying rows of osteoblasts. (The mineralized bone is blue.)
Goldner's modification of Masson's trichrome stain. (Photo-
micrograph supplied courtesy of Dr. Donald Sherrard, VA
Hospital, Seattle, Washington.)
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Fig. 2. Serial levels of serum calcium, phosphorus, and alkaline
phosphatase during treatment with 1,25(OH)2D3. The early fall
in serum phosphorus level and the later rise in both serum cal-
cium and phosphorus are apparent. The latter events occurred
after alkaline phosphatase had fallen toward normal. The prompt
decreases in both serum calcium and phosphorus following the
withdrawal of I ,25(OH)2D3 are evident. (Reproduced from Ref-
erence 74, courtesy of Dr. W. de Gruyter.)
there is little doubt that our patient has significant
secondary hyperparathyroidism.
Pathogenesis of secondary hyperparathyroidism
Before discussing the clinical features of this pa-
tient, I will review the factors thought to produce
Fig. 3. Biopsy obtained after 9 months of treatment with
1,25(OH)2D3, 1.0 p.g/day. There is a marked reduction in marrow
fibrosis and improvement in mineralization, although an increase
in unmineralized osteoid persists. Goldner's modification of
Masson's trichrome stain. (Photomicrograph supplied courtesy
of Dr. Donald J. Sherrard, VA Hospital, Seattle, Washington.)
secondary hyperparathyroidism in uremia. These
pathogenetic factors, believed to originate early in
the course of renal disease, presumably are opera-
tive for many years before the patient manifests
overt bone disease in the late stages of advanced
renal insufficiency [I]. A decrease in ionized cal-
cium in the blood is probably the only important
factor that increases the secretion of parathyroid
hormone (PTH) and leads to the consequent para-
thyroid hyperplasia. Major factors leading to hypo-
calcemia in renal failure include phosphate reten-
tion, abnormalities of vitamin D metabolism, and a
reduced skeletal response to the calcemic action of
PTH. Other conditions, listed in Table 1, also might
be contributory.
Phosphate retention. Slatopolsky et al have sug-
gested that transient and even undetectable in-
crements in serum phosphorus levels occur as GFR
decreases early in the course of renal failure [2].
They argued that such transient hyperphosphatemia
lowers blood calcium and increases PTH secretion,
which in turn reduces the tubular reabsorption of
phosphate and leads to phosphaturia. Thus, serum
phosphorus and calcium levels return toward nor-
mal, but only at the expense of inducing a higher
circulating level of PTH. Considerable evidence,
primarily derived from studies in dogs with reduced
renal function, supports the view that phosphate
retention plays a primary role in the pathogenesis of
secondary hyperparathyroidism in renal failure [3,
4, 5]. A notable problem with this theory is that
such increments in serum phosphorus levels have
1,25(OH)2 Vitamin D3
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not been identified, and, in fact, serum phosphorus
levels are often low or normal in patients with mild
renal insufficiency [6, 7]. When renal function falls
below 25% of normal, overt hyperphosphatemia
frequently develops, and this elevation of serum
phosphorus clearly can be an important factor in the
development of secondary hyperparathyroidism at
this stage of renal failure [8].
Abnormalities of vitamin D ,'netabolism. Strong
evidence indicates that disorders in vitamin D me-
tabolism alter the regulation of calcium and phos-
phorus in uremic patients [9]. It is now apparent
that vitamin D itself, although largely inactive, is a
precursor of more active sterols. Thus, either en-
dogenous or exogenous vitamin D3 first is converted
in the liver to 25-hydroxy-vitamin D3 [10], the major
circulating form of vitamin D [11]. This sterol then
undergoes 1-hydroxylation in the cortex of the
kidney [12] to form I ,25-dihydroxy-vitamin
D3[1 ,25(OH)2D3]. The latter sterol provides a more
potent stimulus to intestinal calcium absorption
than do any of the other forms of the vitamin [13].
The renal generation of 1 ,25(OH)2D3 is subject to
physiologic regulation: it is stimulated by a diet low
in calcium [14], increased levels of PTH [15. 16],
and hypophosphatemia [17]. It can be inhibited by a
high-calcium diet, hyperphosphatemia [17], and
1,25(OH)9D3 itself [18]. Given the central regulatory
role of the kidney in calcium and phosphorus me-
Table 1. Conditions that might contribute to altered calcium
homeostasis and bone disease in renal failurea
A. Hypocalcemia and secondary hyperparathyroidism
I. Retention of phosphate
2. Altered bioactivation of vitamin D
3. Skeletal resistance to PTH
4. Reduced degradation of PTH
B. Defective mineralization of bone
1. Abnormal collagen synthesis
(possibly related to vitamin D)
2. Abnormal crystal growth and maturation
3. Accumulation of pyrophosphate and/or
magnesium in bone
4. Reduced carbonate content of bone
C. Factors of variable and uncertain role
I. Heparin administration
2. Acidosis
3. Phosphate deficiency
4. Vitamin D loss with nephrotic syndrome
5. Skeletal accumulation of trace elements
(e.g., fluoride, aluminum)
6. Modification by treatment
a. Anticonvulsants, other drugs
b. Parathyroidectomy
c. VitaminD
d. Dialysate Ca, Mg, etc.
Adapted from Ref. 91.
tabolism, it is not surprising that vitamin D metabo-
lism is altered in patients with renal insufficiency.
When does this abnormality of vitamin D metabo-
lism develop during the course of progressive renal
insufficiency? A decrease in the generation of
1 ,25(OH)2D3 early in the course of the disease could
lead to both decreased calcium absorption and de-
creased action of PTH on the bone, processes that
in turn would lead to hypocalcemia. Hypocalcemia
would stimulate PTH secretion, which would be ex-
pected to increase the renal generation of
1,25(OH)2Da and to restore serum levels of
1 ,25(OH)2D, intestinal calcium absorption, and
serum calcium to normal; all of these changes
would occur at the expense of an increased level of
serum PTH. The data bearing on the question are
not conclusive; however, the intestinal absorption
of calcium is normal in most patients with mild to
moderate renal insufficiency [7, 19]. Preliminary
studies of blood levels of serum 1 ,25(OH)2D in pa-
tients with early renal insufficiency have yielded
conflicting results. Slatopolsky et al reported nor-
mal or slightly increased levels of 1,25(OH)2D in
adults with creatinine clearances above 30 mllmin
[20], whereas Portale et al found reduced levels in
children with an average GFR of 41 ml/min [21]. It
is possible that high PTH levels maintain the serum
levels of 1,25(OH)2D near normal in azotemic pa-
tients until renal insufficiency becomes marked.
The mechanism of reduced renal generation of
1 ,25(OH)2D3 in patients with mild to moderate renal
insufficiency is uncertain; phosphate retention and
diminished tubular reabsorption of phosphate, both
of which occur early in the course of renal in-
sufficiency, could reduce the generation of
1 ,25(OH)2D3 for any given level of PTH secretion.
Preliminary data of Llach et al suggest that in pa-
tients with mild renal insufficiency, dietary phos-
phate restriction in proportion to the degree of re-
duction in GFR is associated with an increase in in-
testinal calcium absorption and a fall in serum iPTH
[22].
Although we are still uncertain whether vitamin
D metabolism is altered early in the course of renal
insufficiency, most data indicate that the blood lev-
els of 1 ,25(OH)2D3 are low or undetectable in end-
stage uremia [23, 24]. In advanced renal disease, the
lack of 1 ,25(OH)2D3 probably contributes impor-
tantly to the reduced intestinal absorption of both
calcium and phosphorus, the impaired calcemic re-
sponse to PTH, and retarded growth in children.
Moreover, many of these abnormalities can be re-
stored to normal after treatment with doses of
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Fig. 4. Correlation between serum iPTH and serum calcium concentrations during the slow intravenous calcium infusion in ricketic
puppies. The animals were injected with either vehicle alone (A) or 1 jg of l,25(OH)2D3 (B) 4 hours before the initiation of calcium
infusion. Samples collected during the initial 90 minutes of infusion, shown as solid circles, have a continuous regression line, whereas
samples obtained between 90 minutes and 180—200 minutes of the calcium infusion are shown by open circles and an interrupted line.
(Reproduced from Ref. 34 with the permission of The Endocrine Society.)
I ,25(OH)2D3 that are presumably in the physiologic
range [25—29].
Deficiency of 1 ,25(OH)2D3 also could lead to sec-
ondary hyperparathyroidism by virtue of a direct ef-
fect of this sterol on the parathyroid gland.
Brumbaugh et al have described specific cyto-
plasmic receptors, similar to those found in known
target tissues for vitamin D3, for 1 ,25(OH)2D3 in the
parathyroid glands [30]. Moreover, certain data
suggest that I ,25(OH)2D3 can directly inhibit PTH
secretion [31], although such data have not in-
variably been confirmed [32, 33]. Oldham et al sug-
gested that 1 ,25(OH)2D3 might modulate PTH se-
cretion at any given level of blood calcium; data
supporting this view appear in Fig. 4 [34]. In the
absence of I ,25(OH)2D3, a higher level of serum cal-
cium might be needed to produce a similar degree of
suppression of PTH secretion. At this point, such a
suggestion is speculative and further studies are
needed to clarify this possible action of vitamin D.
Despite the low levels of 1,25(OH)2D3 found in
patients with advanced renal failure, many uremic
patients lack features of vitamin D deficiency. In-
testinal calcium absorption is not uniformly reduced
[7, 35] and osteomalacia occurs in only a small frac-
tion of such patients [36, 37]. Moreover, even in
anephric patients bone biopsies often show no his-
tologic evidence of osteomalacia [38]. Why such pa-
tients fail to develop evidence of vitamin D defi-
ciency is not clear. The persistence of normal or
even elevated serum phosphorus levels might pro-
tect uremic patients from osteomalacia; this hy-
pothesis is suggested by the finding that the degree
of osteomalacia is inversely related to serum phos-
phorus levels in end-stage renal failure [39].
Reduced skeletal response to PTH. Skeletal re-
sistance to the calcemic action of PTH also contrib-
utes to hypocalcemia in patients with renal in-
sufficiency. The calcemic response to a standard-
ized infusion of parathyroid extract is subnormal in
patients with moderate to advanced renal in-
sufficiency, and in those undergoing dialysis [40].
Recovery from induced hypocaicemia in patients
with creatinine clearances of 35—90 ml/min is de-
layed as compared to results in normal individuals;
this phenomenon occurs despite a greater augmen-
tation in serum iPTH levels in the patients with mild
renal insufficiency. These observations indicate that
skeletal resistance to PTH appears early in the
course of renal insufficiency [6]. Although the
mechanisms responsible for the impaired calcemic
response to PTH remain uncertain, alterations in vi-
tamin D metabolism have been incriminated [41,
42].
Effect of anticonvulsant drugs. Treatment with
phenytoin (Dilantin®) also might contribute to bone
disease in the patient we are discussing here. The
long-term ingestion of phenytoin, phenobarbital, or
both is associated with a high incidence of osteo-
malacia in nonuremic patients treated for seizure
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disorders [43, 44]. Jubiz et al found low serum lev-
els of 25(OH)D but normal levels of 1 ,25(OH)2D in
patients treated with anticonvulsant drugs who had
clinical evidence of osteomalacia [45]. Hahn et a!
have suggested that these drugs might activate a he-
patic microsomal P-450 enzyme, and that this acti-
vation might lead to abnormal hydroxylation,
changing vitamin D and 25(OH)D3 to biologically in-
active sterols [46]. Pierides et al reported a higher
incidence of symptomatic bone disease in dialysis
patients treated with barbiturates and phenytoin
than in patients not receiving such treatment [47,
48]. Because of the normal serum level of 25(OH)D
in our patient, phenytoin treatment probably did not
contribute significantly to his bone disease. His
serum level of 25(OH)D, however, is lower than
that observed in most residents of southern Califor-
nia, where sunlight exposure is usually substantial.
Clinical inanifestations of renal osteodvstroplzv
Now I should like to examine the clinical mani-
festations in this patient. Bone pain that develops
with renal osteodystrophy is often subtle and in-
sidious in onset; the axial skeleton—back, hips, and
ribs—is most commonly involved, but pain can in-
volve the knees, heels, and shoulders. Symptoms
are often aggravated by sudden changes in position,
e.g., when the patient turns over in bed or sits up.
Because the pain is related to motion, patients often
become sedentary and sometimes even bedridden.
Symptoms can be independent of the specific type
of skeletal pathology present. Pain might be worse
at night, but little relationship exists between the
bone pain and temperature or climate. Physical
findings usually are absent; consequently, the
symptoms commonly are attributed to minor
trauma or a psychosomatic cause. The degree of
pain does not necessarily correlate with the extent
of radiographic abnormalities; thus, patients with
severe lesions can be free of symptoms, although it
is somewhat unusual for patients to be symptomatic
in the absence of radiographic abnormalities. Many
other signs and symptoms have been associated
with high levels of PTH [Table 2]. Massry and Gold-
stein recently suggested that PTH might even be a
uremic toxin [49].
I believe that the patient's muscle weakness de-
serves some attention, because this symptom is
commonly overlooked despite the fact that myopa-
thy occurring in conjunction with renal osteo-
dystrophy is very common. We recently presented
our experience with 7 uremic patients who had se-
vere proximal muscle weakness [50]; all but one had
Table 2. Clinical manifestations of calcium and phosphorus
abnormalities in renal failurea
Bone pain Acute periarthritis
Myopathy Hypertension
Pruritus Spontaneous tendon rupture
Muscle cramps Calciphylaxis
Fractures Neuropathy
Retardation of growth Altered mentation
Skeletal deformities Impotence
Pseudogout Pancytopenia
Adapted from Nortman DF, Coburn JW, Postgraduate
Medicine, vol 64, no 5, Nov 1978, © McGraw-Hill, Inc.
been treated with long-term maintenance dialysis,
and the slowly progressive symptoms had existed
for an average of 24 months before treatment. Ab-
normalities of gait were present in all patients; 3 pa-
tients exhibited a waddling, "penguin" gait that is
characteristic of the proximal myopathy of vitamin
D deficiency [51]. Two patients had weakness when
they elevated their arms, and they experienced dif-
ficulty in combing or setting their hair. Of the 7 pa-
tients, 6 had difficulty rising from a chair and were
unable to climb stairs. Depite evidence of proximal
weakness, distal muscle strength, e.g., strength of
the hand grip, frequently was normal. The myopa-
thy is associated with normal serum enzymes,
creatinine phosphokinase, and transaminase; elec-
tromyographic changes are usually nonspecific.
Because of its slow, insidious nature, the myopa-
thy often is overlooked or attributed to debility in
dialysis patients who have other evidence of chron-
ic illness. Although the pathogenesis of proximal
myopathy in patients with chronic renal failure re-
mains uncertain, muscle weakness has been attrib-
uted to hyperparathyroidism [52], phosphate deple-
tion [53], and abnormal vitamin D metabolism [51,
53]. We and others have observed significant,
prompt improvement in muscular weakness during
treatment with l,25(OH)9D3 [27]. Our finding of
such muscle weakness in patients who have
markedly elevated, normal, or even undetectable
levels of serum iPTH suggests that factors other
than PTH play a pathogenetic role. We have noted
serum calcium levels of 8.1 to 11.3 mgldl and serum
phosphorus levels of 2.9 to 5.5 mg/dl in patients
with myopathy. Moreover, myopathy has improved
during treatment with 1 ,25(OH)2D3 even without a
change in serum levels of calcium or phosphorus. In
2 patients, muscle strength improved while serum
iPTH levels remained unchanged. Moreover, bone
biopsies from 5 patients revealed divergent results:
we found osteomalacia in 2, marked osteitis fibrosa
in one, and "mixed" lesions in 2 others. In one pa-
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tient, a muscle biopsy revealed atrophy of type-2
fibers, a finding typical of the myopathy associated
with vitamin D deficiency [54]. Electron micro-
scopic examination of muscle biopsies in uremic pa-
tients has revealed severe degenerative changes,
with disorganization of myofibrils and dispersion of
Z-band material; these abnormalities reverted to
normal following treatment with 25(OH)D3 [55].
Altered muscle contraction and relaxation have
been reported in vitamin D-deficient animals [56].
Defective calcium uptake by the sarcoplasmic retic-
ulum in skeletal muscle has been noted with vita-
min D deficiency [57] and experimental uremia [58];
moreover, treatment of uremic animals with
1 ,25(OH)2D3 reversed this abnormality [58]. Altered
calcium transport by the sarcoplasmic reticulum of
muscle could arise from abnormal vitamin D metab-
olism. The mechanism whereby l,25(OH)2D3 af-
fects muscle function is unknown, because specific
1 ,25(OH)9D3 receptors resembling those found in
other target tissues, such as the kidney, intestine,
and parathyroid glands, appear to be absent in
muscle [59]. Why muscular weakness does not oc-
cur more often in uremia is uncertain, since low
plasma levels of I ,25(OH)2D3 are common in pa-
tients with advanced renal failure [23, 24].
Some additional comments regarding the clinical
and biochemical findings in this patient are worth-
while. He had no evidence of skeletal disease when
his advanced, chronic renal insufficiency was first
identified. Moreover, he developed significant Os-
teitis fibrosa despite reasonable control of serum
phosphorus levels. Careful maintenance of normal
serum phosphorus levels clearly can reduce the in-
cidence of secondary hyperparathyroidism [60], but
significant symptoms still develop in some patients,
perhaps because therapy is not initiated until long
after parathyroid hyperplasia is well established.
The elevation of plasma alkaline phosphatase,
which occurs slowly over many weeks or months in
patients with bone disease, has not been a useful
differentiating factor for the type of bone disease.
Interpreting serum PTH assays
Before proceeding to the issues of diagnosis and
management of renal osteodystrophy, a few com-
ments about the determination of serum iPTH are
necessary. Many clinically available assays for
serum iPTH utilize antisera that primarily detect the
carboxyl-terminal fragments of PTH. It now seems
certain that the native PTH molecule, a single-chain
peptide of 84 amino acids, is quickly cleaved by the
liver into amino-terminal and carboxyl-terminal
fragments [61, 62]; the carboxyl-terminal fragments
are inactive but remain in the circulation with a
longer "half-life" than either the 1-84 intact PTH
molecule or the biologically active, 1-34 amino-ter-
minal fragment. Moreover, these carboxyl-terminal
fragments are not degraded by the liver but rely en-
tirely on the kidney for degradation and clearance
from the blood [63]. The plasma half-life of carbox-
yl-terminal fragments is markedly prolonged when
renal function is decreased, and serum iPTH levels,
measured with antisera directed toward the car-
boxyl terminal moiety of the PTH molecule, often
are markedly elevated [64, 65]. Serum iPTH in the
patient under discussion today was measured in the
research laboratory of Dr. Frederick Singer, with
the Burroughs Wellcome antiserum 211/32. This
antiserum is directed in large part toward the intact
PTH molecule. Thus, the serum iPTH level that
was fivefold higher than normal is quite significant;
such a degree of elevation with an assay utilizing a
carboxyl-terminal antiserum might be normal" for
uremia. A good correlation has been reported be-
tween serum iPTH levels, measured with a carbox-
yl-terminal antiserum, and morphometric changes
in bone due to secondary hyperparathyroidism [65];
unfortunately, such data are not available for many
widely used assays of iPTH. For the appropriate
use of serum iPTH measurements, the physician
should know the degree of elevation of serum iPTH
that occurs in uremic patients simply because of the
retention in the circulation of biologically inactive
fragments [63]. Ideally, one also should use a PTH
immunoassay that correlates with the histomorpho-
metric bone findings of secondary hyper-
parathyroidism; unfortunately, such data are not
currently available.
Diagnosis of renal osteodystrophv
With the observation of high levels of serum
iPTH and radiographic findings of subperiosteal re-
sorption in our patient, the bone biopsy finding of
osteitis fibrosa is not surprising. Although obtaining
a properly undecalcified specimen from a bone
biopsy is the most desirable way to diagnose skele-
tal lesions, appropriate radiographic techniques al-
so can be very useful. The use of fine-grain x-ray
film combined with magnification of the x-rays can
greatly increase the sensitivity of x-rays in detecting
abnormalities and can aid in the follow-up of pa-
tients, particularly when the films are viewed by a
radiologist with expertise in metabolic bone disease
[66, 67]. The use of fine-grain, industrial-quality x-
ray film is not popular with radiology departments
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because these films cannot be developed automati-
cally; however, film ordinarily used for mammogra-
phy can be a satisfactory substitute. Meema and his
colleagues reported that the use of fine-grain x-ray
film and magnification techniques remarkably im-
proves the radiologist's ability to detect osteitis
fibrosa [67-69]. In patients with secondary hyper-
parathyroidism, cortical striations frequently are
seen in the shafts of the phalanges and metacarpals,
and presumably represent enlarged haversian ca-
nals within the bone [67]. The x-ray techniques ca-
pable of detecting osteomalacia are far less sensi-
tive; in our experience, pseudofractures or Loos-
er's zones are unusual in uremic patients with
osteomalacia [70]. Radiographic signs of rickets can
develop in children, but such findings are not help-
ful after closure of the epiphyses. The x-rays of pa-
tients with osteomalacia usually show only demin-
eralization or osteopenia.
Recent data from laboratories in Germany [71],
the United Kingdom [72], and this country [37, 73]
indicate the existence of distinct subcategories of
metabolic bone disease in patients with kidney dis-
ease. Moreover, the type of skeletal disease is im-
portant in determining the patient's response to
treatment with 1 ,25(OH)2D3 or other active vitamin
D sterols. Our work with these subgroups of bone
disease was conducted in conjunction with Drs.
Donald Sherrard, Arnold Brickman, Frederick
Singer, Eugene Wong, and Anthony Norman. We
evaluated bone biopsies by quantitative morpho-
metric techniques in approximately 60 highly se-
lected uremic patients who were treated with
l,25(OH)2D3 or la(OH)D3 [73—77]. Repeat bone
biopsies were performed in many patients after 6 to
12 months. These patients, all of whom had ad-
vanced renal failure and most of whom were under-
going dialysis, were selected because of the pres-
ence of symptomatic bone disease, marked radio-
graphic abnormalities, or both. The patients
comprised four distinct categories (Table 3). One
group, of which the patient presented today is rep-
resentative, had osteitis fibrosa with substantial
marrow-space fibrosis and increased bone turnover
as measured by double tetracycline labeling.
Biopsies from this group frequently exhibited an in-
crease in unmineralized osteoid that lay beneath ac-
tive osteoblasts; such unmineralized osteoid arises
because of a lag in mineralization of newly formed
matrix rather than because of defective mineral-
ization.
A second group has been termed "mild." The
bone biopsies in these patients revealed less than
Table 3. Skeletal lesions in 50 patients with severe renal
osteodystrophya
Fraction of surface area
Afflicted
%
Mineralized
%
Fibrosis
%
Osteitis fibrosa
Mild
Osteomalacia
Mixed
39
15
33
13
> 80
> 85
< 80
< 80
> 2.0
< 0.6
< 1.5
> 2.0
Normal — > 94 0
a Modified from Ref. 73.
0.1% of marrow space filled with fibrosis but
showed increased resorption surface. These pa-
tients characteristically have increased serum iPTH
levels. Few patients with symptomatic bone disease
have this type of skeletal pathology; most have re-
sponded favorably to treatment with 1 ,25(OH)9D3.
Bone biopsy in a third subgroup showed osteo-
malacia with wide osteoid seams (greater than 20%
of the bone surface not mineralized); tetracycline
labeling revealed a delay in mineralization, with
slow bone turnover. Biopsy in the fourth group
showed mixed lesions," with evidence of both os-
teitis fibrosa and osteomalacia; these patients had
evidence of high bone turnover, but the areas of un-
mineralized osteoid were substantially greater than
in patients with osteitis fibrosa alone. Serum iPTH
levels measured with the antiserum described
above correlated well with marrow fibrosis; strik-
ingly elevated levels of serum iPTH were present
only in the patients with osteitis fibrosa or "mixed
lesions."
The patients with osteitis fibrosa or pure osteo-
malacia were separated into two subgroups on the
basis of their response to treatment with
l,25(OH)2D3 (Table 4). Patients with osteitis fi-
brosa, by far the largest subgroup, showed an im-
provement in symptoms and a decrease in serum
iPTH and alkaline phosphatase. Sequential bone
biopsies revealed substantial improvement, with
reduction in marrow-space fibrosis and improved
bone mineralization. The patient under discussion
today is representative of this group. A smaller
subgroup of patients with biopsy-proved osteitis
fibrosa exhibited a rapid increase in serum calcium
levels during treatment with 1 ,25(OH)2D3; this hy-
percalcemia necessitated withdrawal of therapy.
Neither serum levels of iPTH, alkaline phospha-
tase, nor the extent of bone abnormalities differed
in these two subgroups. On the other hand, serum
calcium levels exceeded 10.5 to 11.0 mg/dl before
initiation of treatment with l,25(OH)2D3 in the
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patients who developed marked hypercalcemia. At
subsequent surgery or at autopsy, the latter group
of hypercalcemic patients was found to have mas-
sive parathyroid hyperplasia. These observations
suggest that treatment with l,25(OH)2D.3 might aid
in the identification of patients needing parathyroid
surgery [78].
The patients with pure osteomalacia also com-
prised two subgroups, which were determined by
the response to treatment with 1,25(OH)2D3. The
patients in one subgroup showed no improvement
of symptoms during treatment with 1 ,25(OH)2D3;
the serum iPTH levels were normal or undetectable
and the bone biopsies disclosed no marrow-space
fibrosis or increase in resorptive surface. These pa-
tients had a tendency to develop hypercalcemia
during treatment with either I ,25(OH)2D3, another
form of vitamin D, or even oral supplements of cal-
cium alone. Indeed, the marked propensity for de-
veloping hypercalcemia suggested that bone was
not significantly contributing to the "buffering" of
extracellular calcium [76]. Repeated bone biopsies
showed no improvement after prolonged treatment
with I ,25(OH)2D3 even though the serum calcium
was sustained above normal. Plasma levels of
25(OH)D were either normal or elevated, perhaps
because of prior treatment with vitamin D3. Thus,
such patients appear to have defective bone miner-
alization that is related neither to levels of calcium
or phosphorus in the extracellular fluid nor to treat-
ment with vitamin D. These patients often had re-
current rib and hip fractures and back pain, and
they experienced progressive debility. Patients
from the Newcastle area of the United Kingdom
have exhibited a similar clinical picture [79, 80];
their skeletal disease has been attributed to exces-
sive levels of aluminum in the tap water used for the
preparation of dialysate [81]. Epidemiologic data
from sporadic patients in the United States fail to
implicate aluminum in tap water, and the cause of
this disease remains obscure [76].
The other subgroup with predominant osteo-
malacia had pretreatment levels of serum calcium
that were generally below 10.5 mg/dl, serum iPTH
levels that were slightly above normal, and small
areas of marrow fibrosis on bone biopsy. These pa-
tients exhibited clinical improvement during treat-
ment with 1 ,25(OH)2D3, although the bone mineral-
ization recovered only partially following treatment
with 1 ,25(OH)2D3 for 6 to 12 months.
For the entire group of patients treated with
1 ,25(OH)2D3, the major pretreatment observations
that were useful in predicting a favorable response
to 1 ,25(OH)2D3 included a serum calcium level be-
low 10.5 mgldl and some elevation of serum iPTH
levels (Table 4). A similar separation of patients
with renal osteodystrophy during treatment with
la(OH)D3 has been reported by investigators in
the United Kingdom [80, 82, 83].
Management ofrenal osteodystrophy
Before discussing the therapeutic use of
1 ,25(OH)2D (Rocaltrol®) in the patient presented
today, I should like to comment regarding general
principles of managing altered calcium and phos-
phorus metabolism in uremia. The management ob-
jectives for altered divalent ion metabolism should
be: (I) maintaining the blood levels of calcium and
phosphorus as near normal as possible; (2) pre-
venting the development of parathyroid hyperplasia
Table 4. Serum biochemical observation before and after treatment with 1 ,25-dihydroxy-vitamin D3 in uremic patients
Type of
bone No. of
disease patients
Response
to Rx
Serum 'PTHe Calcium Phosphorus Alkaline phosphatase
C T
lU/mi
25(OH)D
C
nglml
C T'
ng/mI
C T
mg/dl
C T
mgld!
Osteitis 21
fibrosa 4
Osteo- 10
malacia 6
Mild 7
Mixed 8
R
Fd
F
R
R
R
2.8 0.3 1.0 0.3
3.1 0.4 2.2 0.5
0.2 0.1 —
1.5±0.7 0.4±0.1
1.5±0.3 0.4±0.1
2.1±0.7 0.6±0.2
9.4 0.2 10.1 0.3
11.1 0.3 17.8 0.9
10.5 0.2 11.8 0.2
8.7±1.8 9.8±0.9
9.8±0.1 10.3±0.3
7.2±0.4 8.8±0.3
4.5 0.2 5.0 0.3
5.8 0.6 5.7 0.9
4.7 0.1 5.1 0.2
5.9±0.6 5.1±0.7
4.4±0.5 5.0±0.3
4.6±0.3 4.8±0.3
297 61 139 35
173 26 260 109
174 15 219 23
259±133 153± 76
121± 34 80± 22
501±153 137± 41
38 4
—
58 10
31± 7
—
25±4
a C = control, pre-treatment values.T = values at end of treatment.
R responders.
F = treatment-failure group.
Measured with Burroughs Welicome antisera.
All data are mean SE.
Modified from Ref. 77.
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or, if secondary hyperparathyroidism is already es-
tablished, suppressing PTH secretion; (3) restoring
the skeleton to normal; and (4) preventing and/or
reversing extraskeletal deposition of calcium. Of
these factors, the control of serum phosphorus is
probably the most important and can be accom-
plished by moderately restricting the dietary intake
of phosphorus to 0.8 to 1.0 glday and by adminis-
tering aluminum hydroxide or aluminum carbonate
to bind phosphate in the gut. Because of the varia-
bility of phosphorus absorption in patients with ure-
mia, the dosage of aluminum-containing com-
pounds must be adjusted on an individual basis.
Serum phosphorus levels should be measured every
2 to 4 weeks to avoid either hyper- or hypophospha-
temia, as the latter can predispose to osteomalacia.
Dietary calcium intake should be adequate. We cur-
rently recommend oral calcium supplements that
provide 1.0 gram of calcium per day; calcium is pre-
scribed only when the serum phosphorus level is
controlled. The dialysate calcium concentration
should be maintained at 6.0 to 6.5 mg/dI (3.0-3.25
mEq/liter) to prevent either the loss or gain of cal-
cium during dialysis.
The indications for the use of vitamin D sterols
are only currently being established. These com-
pounds should not be given to patients who have
uncontrolled hyperphosphatemia (i.e., serum phos-
phorus > 6.0 mg/dl). After the serum phosphorus
has been controlled, vitamin D sterols are in-
dicated: (1) in the presence of hypocalcemia unre-
sponsive to calcium supplementation through diet
or dialysis; (2) when there is evidence of overt sec-
ondary hyperparathyroidism, particularly when the
serum calcium is below 11.0 mg/dl; (3) for osteo-
malacia, particularly when it coexists with second-
ary hyperparathyroidism; (4) in children with
chronic renal failure [291; (5) when the need exists
for concomitant anticonvulsant therapy: and (6) in
patients who exhibit symptoms of proximal myopa-
thy. It is not yet known whether vitamin D should
be used prophylactically in all patients with end-
stage renal disease.
Other management considerations include (1) the
use of appropriate levels of dialysate magnesium
(0.5-0.7 mEq/liter) to avoid hypermagnesemia [84];(2) the use of water treatment in preparation of
dialysate to remove fluoride and aluminum, and to
regulate calcium and magnesium levels; (3) avoidance
of unnecessary treatment with barbiturates, pheny-
tom, and comparable drugs; and (4) maintenance of
normal acid-base status. The specific benefits of
some of these measures have not been firmly estab-
lished, however.
The man described today illustrates several char-
acteristics of patients with severe osteitis fibrosa
who respond favorably to treatment with
1 ,25(OH)2D3. Symptoms usually improve within I
to 2 months after initiation of treatment [74, 77], al-
though symptomatic improvement can be delayed
on occasion [85]. Serum alkaline phosphatase can
rise during the first few weeks of treatment and then
slowly fall toward normal. The serum calcium level
might not increase during the first several weeks or
months of treatment, even with doses of
1,25(OH)2D3 as large as 1.0 pjg/day; this is particu-
larly true in patients with radiographic evidence of
extensive skeletal disease. The serum phosphorus
levels, obtained immediately before each dialysis,
often decrease significantly during the first month of
treatment and slowly increase thereafter. After 8
months of treatment, our patient developed signifi-
cant hyperphosphatemia despite an increase in the
dosage of aluminum hydroxide. It is well recog-
nized that I ,25(OH)2D3 increases intestinal absorp-
tion of calcium and phosphorus [26, 86]. Serum cal-
cium and phosphorus might not increase during the
initial period of treatment because of substantial
remineralization of the skeleton. Later, when serum
alkaline phosphatase has decreased, serum calcium
and phosphorus levels commonly increase. This pa-
tient illustrates a significant relationship between
the development of hypercalcemia and a decrease
of serum alkaline phosphatase to normal during
treatment with I ,25(OH)2D3. A reduction in the dos-
age of 1 ,25(OH)2D3 is indicated when the alkaline
phosphatase decreases to normal. This patient ex-
hibits another common finding seen during treat-
ment with 1,25(OH)2D3, a prompt fall in the serum
levels of both phosphorus and calcium shortly after
withdrawal of treatment. A major advantage of
1 ,25(OH)2D3 over other forms of vitamin D is the
short persistence of a biologic effect after the
withdrawal of treatment [87, 88]. Thus, this sterol
can be used more safely than other forms of vitamin
D that act for a longer time after the drug is discon-
tinued [89].
Finally, parathyroidectomy should be reserved
for patients with definite evidence of secondary hy-
perparathyroidism (subperiosteal erosions and sig-
nificantly increased iPTH levels). Surgery might be
indicated in these patients if they also have per-
sistent hypercalcemia, progressive or symptomatic
extraskeletal calcification, a persistently elevated
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serum calcium x phosphorus product that is recal-
citrant to other therapy, or calciphylaxis [90].
Questions and answers
DR. J. P. KASSIRER: Before 1,25(OH)9D3 or
la(OH)2D3 were available, a number of groups re-
ported that patients who had substantial renal
osteodystrophy, particularly osteitis fibrosa, re-
sponded effectively to vitamin D2 or other vitamin
D preparations. The problem was that these pa-
tients frequently developed sustained hyper-
calcemia. The question is, what is the course of the
hypercalcemia induced by I ,25(OH)2D3? Does it
typically respond promptly to reduction or elimina-
tion of therapy? Do you sometimes have to treat the
hypercalcemia by other means?
DR. COBURN: One of the major advantages of
1 ,25-dihydroxy-vitamin D over other forms of vita-
min D is its relatively short half-life: the circulating
half-life is probably 3 to 5 hours, although its biolog-
ic effect might be somewhat longer. Nonetheless,
when one discontinues the drug, the hypercalcemia
usually abates within 2 to 3 days without special
treatment. Only rarely are special procedures, such
as dialysis with a calcium-free dialysate, needed.
DR. KASSIRER: The response in the patient dis-
cussed today is apparently typical of patients who
receive l,25(OH)2D3; not only do their serum cal-
cium levels rise, but their serum phosphorus levels
rise as well. Why do you worry about the rise in
serum phosphorus levels in these patients? Are you
concerned about it only because of the possibility of
metastatic calcification or do you have other rea-
sons?
DR. COBURN: The appearance of phosphate re-
tention and hyperphosphatemia causes one to wor-
ry, not only because secondary hyperparathy-
roidism is aggravated but because an elevated cal-
cium x phosphorus product increases the risk of
extraskeletal calcification. We have seen no in-
crease in serum iPTH when serum phosphorus is
raised during therapy with I ,25(OH)9D3, possibly
because the serum calcium is usually slightly high-
er, and also because of the action of I ,25(OH)2D3 on
the parathyroid glands.
DR. J. J. COHEN: You indicated that patients who
have predominant osteomalacia histologically do
not respond predictably to the administration of vi-
tamin D preparations. Isn't it paradoxical that the
one bony change thought to be the specific con-
sequence of vitamin-D deficiency does not respond
to hormone replacement as well as the bone disease
due to parathyroid excess does?
DR. COBURN: In patients with exclusive osteo-
malacia and normal or increased plasma levels of
25-hydroxy-D, we have given l,25(OH)2D3 and
raised their serum calcium levels to above normal
for weeks or even months in an effort to improve
their severe, symptomatic bone disease. We also
have allowed serum phosphorus levels to increase
in an effort to induce healing. If one increases serum
calcium and phosphorus levels in the osteomalacia
secondary to vitamin D deficiency, the unmineral-
ized osteoid will calcify. We believe that the failure
of healing in the uremic patient represents an abnor-
mality of bone matrix that is unrelated to levels of
serum calcium or phosphorus, or to an abnormality
affecting vitamin D. Morphologically, this disorder
appears the same as one described in England in an
area around Newcastle on Tyne. In England the
condition has seen blamed on the presence of ex-
cess aluminum in the tap water used to prepare
dialysate [81, 93]; however, the 18 or 20 dialysis pa-
tients we have seen with this disorder come from
diverse areas of the country. Because many other
patients who have undergone dialysis in the same
units have not developed bone disease, I do not
think one can justify blaming such sporadic cases
on excess aluminum in the water supply. In a pre-
liminary study, we have measured bone aluminum
in several of these patients and in dialysis patients
with other types of bone disease. The bone alumi-
num levels were above normal in all, but they were
higher in the patients with this mineralizing defect
than in patients with other types of bone disease
[94]. Serum iPTH levels also were lower than in
other uremic patients. Thus, the accumulation of
aluminum or other trace elements in bone, and the
low levels of serum iPTH might contribute to defec-
tive mineralization. The source of aluminum is un-
certain but might be related to ingestion of phos-
phate-binding antacids in the sporadically occurring
cases. Such patients might have increased intestinal
permeability to aluminum or an abnormality of bone
matrix leading to aluminum accumulation; obvious-
ly, these comments are speculative.
DR. COHEN: What you are calling osteomalacia,
therefore, should not be interpreted as being related
specifically to vitamin D deficiency.
DR. COBURN: That is correct. Osteomalacia is a
descriptive term used to indicate defective mineral-
ization of bone, no matter what the cause.
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DR. BORIS SENIOR (Chief, Division of Pediat-
ric Endocrinology, NEMCH): Two questions: Is a
decreased response to 1 ,25(OH)2D3 ever caused by
poor calcium absorption from the gut in patients
with renal failure? Do uremic patients generate less
calcium-binding protein in response to 1 ,25-dihy-
droxycholecalciferol?
DR. COBURN: In an extensive study, we exam-
ined the relationship between the dose of
1,25(OH)2D3 and the change in intestinal calcium
absorption during the oral administration of
l,25(OH)2D3 in patients with chronic renal failure
and in normal individuals [86]. We could stimulate
calcium absorption just as readily in the uremic pa-
tients as in normals. Also, the patients with osteo-
malacia who do not improve readily become hyper-
calcemic when they are given small doses; thus, we
conclude that their intestines are responding to
1 ,25(OH)2D3. It should be noted that we are giving a
hormone by mouth that is normally produced in the
kidney and then enters the blood stream. It is pos-
sible that the intestinal cells might "see" the hor-
mone first in larger amounts than might occur if the
drug were administered intravenously. Perhaps the
effect of 1 ,25(OH)2D3 should be evaluated using an-
other route of administration.
Blood levels of 1 ,25(OH)2D3 have been measured
only recently and only in occasional patients. One
child, with typical osteitis fibrosa, responded slug-
gishly and had blood levels of 1,25(OH)2D3 that
were lower than might be expected, suggesting poor
absorption of the sterol. This problem obviously
needs to be explored further.
DR. MARCK MOLITCH (Division of Endocrinolo-
gy, NEMCH): Some patients with modest renal in-
sufficiency have had an acceleration of renal failure
when treated with 1 ,25(OH)2D3, I would like to hear
your comments on this observation.
DR. COBURN: One report from Denmark [95] in-
dicates that patients with creatinine clearances of
15—40 ml/min who received 1,25(OH)2D experi-
enced small but reversible increases in serum
creatinine compared to a "placebo" group given
only a very small dose of vitamin D. I wonder
whether the augmented absorption of phosphorus
or calcium that is stimulated by 1 ,25(OH)2D3 might
worsen renal function. Animal experiments [96] and
clinical studies by Walser and colleagues [97] sug-
gest that glomerular filtration rate might improve in
renal failure during phosphate depletion. These tri-
als of 1 ,25(OH)2D3 should be repeated with careful
attention to phosphate homeostasis; the researchers
should ensure that phosphate retention does not oc-
cur.
DR. SENIOR: Some have suggested that any ad-
verse effect of 1 ,25-dihydroxycholecalciferol on
renal function results from hypercalcemia. Do you
agree?
DR. COBURN: Certainly hypercalcemia could
worsen renal function. However, the animal experi-
ments that I cited indicate that renal failure progress-
es in a subtotally nephrectomized rat fed a regular
diet. When the diet is depleted of phosphate, renal
function improves. The serum calcium levels usual-
ly are higher in the phosphate-depleted rat than in
the rat fed a normal diet. Thus, the change in renal
function could arise from either calcium or phos-
phate retention.
DR. MOLITCH: I am intrigued by the subgroup of
uremic patients who have normal calcium levels
and normal or low PTH levels. What is the ex-
planation for these findings?
DR. COBURN: That is a very interesting question.
The regulatory mechanisms that control serum cal-
cium and calcium balance in these patients are not
understood. Several patients have exhibited a ten-
dency to become hypercalcemic with oral calcium
loads, very small doses of either vitamin D2 or
1,25(OH)2D3, or exposure to high calcium-con-
taining dialysates. Without the presence of func-
tioning kidneys to excrete calcium, such patients
have lost one mechanism for regulating serum cal-
cium; the bone behaves as though it does not partic-
ipate in the "buffering" of extracellular fluid cal-
cium. Thus, these patients seem to have a very
small miscible calcium pool and can develop pro-
tracted hypercalcemia when any calcium is admin-
istered because they have no means of excreting
calcium. Why this should occur, I do not know. It
would be well to test calcium kinetics to resolve the
question of the pool size; this study has not been
done because such patients are seen only sporadi-
cally and because regular dialysis would complicate
such an evaluation.
Six or seven of our patients with these findings
had undergone parathyroidectomy for preexisting
well-documented osteitis fibrosa. In these patients,
hyperparathyroid bone disease might have been
converted to the less common disorder, osteo-
malacia. The tendency toward normal or even
slightly increased serum calcium levels might be re-
sponsible for preventing hyperparathyroidism in the
others; we are beginning to evaluate the parathyroid
response to acute hypocalcemia in these patients.
Thus, a primary failure of the parathyroid glands
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could exist, and the low levels of serum iPTH could
contribute to the decreased bone turnover.
DR. SERAFINO GARELLA (Chief, Division of Re-
nal Diseases, Rhode Island Hospital, Providence,
Rhode Island): Do you use bone densitometry in
diagnosing renal osteodystrophy?
DR. COBURN: Bone densitometry only tells you
the amount of bone mineral and provides no infor-
mation about its cause. A low value can occur with
osteoporosis, osteomalacia, or other bone dis-
orders. I think bone densitometry is a useful adjunct
in monitoring a patient's course of therapy, but it
should be used with other studies such as careful
bone x-rays to help explain the qualitative aspects
of bone changes.
DR. GARELLA: Except for its duration of action,
the activity of dihydrotachysterol appears similar to
that of 1 ,25-dihydroxy-vitamin D in treating some of
these conditions. Do you know of another major
difference?
DR. COBURN: Dihydrotachysterol (DHT) is a
non-natural sterol, discovered somewhat by acci-
dent in the laboratory. Because physiologists and
biochemists are less interested in this quirk of the
laboratory than in natural sterols, we know far less
about the action of DHT on bone than we do about
the more recently identified, naturally occurring
sterois. Dihydrotachysterol must be 25-hydroxy-
lated before it acts, and the dose required for action
is larger than that needed for 25(OH)D3, and almost
as high as that for vitamin D2 itself. The action of
DHT can be ineffective in patients with liver disease
or those taking anticonvulsant medications. Also,
there seems to be more variability in the doses
needed to produce a given effect than is the case for
l,25(OH)2D3. We have found beneficial effects of
l,25(OH)2D3 in several patients who allegedly had
received DHT in doses as large as 2 mg/day. How-
ever, a carefully controlled comparison of the ef-
fects of DHT and 1 ,25(OH)2D3 has not been per-
formed.
DR. GARELLA: Do you have any suggestions re-
garding the treatment of patients who suffer primar-
ily from osteomalacia?
DR. COBURN: I wish I did. The results of various
therapeutic maneuvers have been equivocal or neg-
ative in most patients. We have tried reducing the
ingestion of aluminum hydroxide to ensure that
there is no phosphate depletion. In some we have
replaced the acetate in the dialysis bath with bi-
carbonate; in others we have tried lowering dialy-
sate magnesium so that hypermagnesemia does not
exist; and in some, we have initiated special treat-
ment of tap water to reduce trace metals. There was
no apparent benefit from any of these treatment mo-
dalities. The patients with osteomalacia often are
bedridden, and some have actually died because of
deformities of the chest or spine produced by their
bone disease. We have given some of these patients
I ,25(OH)2D3, and a few have exhibited decreased
pain, improved muscle strength, and a decrease in
serum alkaline phosphatase to normal. Improve-
ment as shown by bone biopsy was negligible, how-
ever. The patients who had a clinical response to
1 ,25(OH)2D3 tolerated larger daily doses before de-
veloping hypercaicemia than did those who failed to
respond [94].
We currently are evaluating another naturally oc-
curring vitamin D sterol—24,25-dihydroxy-vitamin
D3 [98]; this sterol is believed by some to stimulate
bone formation, although others believe it is merely
a degradation product of vitamin D. Preliminary re-
suits with 24,25(OH)2D3 in a few patients show a
decrease in serum calcium and a greater tolerance
for 1,25(OH)2D3 or DHT without causing hyper-
calcemia. Most such patients given 24,25(OH)2D3
with either 1 ,25(OH)2D3 or DHT have shown chem-
ical, biochemical, and histologic improvement [99].
We have little idea about the pathogenesis of this
type of osteomalacia. It might represent several dif-
ferent diseases; for example, cadmium excess might
be a cause in one patient, aluminum excess in an-
other, and deficiency of 24,25(OH)2D3 in yet anoth-
er. Obviously, I am speculating.
DR. MARTIN GELMAN (Renal Division, St. Eliza-
beth's Hospital, Boston, Mass.): Slatopolsky has
had some success treating osteomalacia using 25-
hydroxy-vitamin D3. Have you had a similar ex-
perience?
DR. COBURN: In a multi-center trial with 25-hy-
droxy-vitamin D3, the patients were separated into
those who responded well—usually patients with
secondary hyperparathyroidism—and those who
didn't. Patients with osteomalacia who were treated
with 25-hydroxy-vitamin Dg failed to respond. The
observation that serum levels of 25(OH)-vitamin D3
were normal or high in our patients led us away
from a therapeutic trial with this sterol.
DR. DONALD HRIcIK (Renal Fellow, NEMCH):
Should we be using "phosphate binders" and diet-
ary phosphate restriction in patients with progres-
sive renal disease before overt hyperphosphatemia
develops?
DR. COBURN: You can marshall strong arguments
for doing so; Slatopolsky, Bricker, and colleagues
have presented convincing evidence that you
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should [2-5]. This program can reduce serum iPTH
levels, but long-term studies have not evaluated its
safety. In countries in which people eat diets lower
in phosphate than those consumed in the U.S., a
high incidence of osteomalacia has been reported.
Thus, one might be trading secondary hyper-
parathyroidism for another type of bone disease.
Studies are needed to evaluate this question.
DR. NIcoLAos E. MADIAS iRenal Service,
NEMCH): Are there any data on the levels of
1,25(OH)2-vitamin D in human acute renal failure?
DR. COBURN: None of which I am aware.
DR. ROBERT RUBIN (Chief of Nephrology, Le-
muel Shattuck Hospital, Boston): Your comments
regarding treatment for uremic myopathy are inter-
esting. Do you have any quantitative data in pa-
tients whom you have treated with 1,25(OH)2D3?
DR. COBURN: The data I presented are based on a
clinical, retrospective analysis of patients who were
identified because of symptoms thought to arise
from bone disease. We now are carrying out a
double-blind prospective study in dialysis patients,
using clinical tests of muscle strength as an index of
myopathy, but we do not yet have data available. I
mentioned our experience because most physicians
are not aware of the myopathy and its potential re-
versibility.
DR. COHEN: Would you summarize what you re-
gard as the indications for parathyroidectomy in pa-
tients with end-stage renal disease?
DR. COBURN: Yes. Several syndromes can be im-
proved with parathyroid surgery. Before para-
thyroidectomy is considered, secondary hyper-
parathyroidism must be verified by either (1) a bone
biopsy showing osteitis fibrosa, (2) an x-ray show-
ing subperiostal absorption, or (3) markedly ele-
vated serum iPTH levels, measured with an assay
that correlates well with bone disease. When one of
these criteria is met, surgery may be considered un-
der several situations. When a uremic patient devel-
ops spontaneous hypercalcemia, I would consider
parathyroidectomy. If a patient with documented
secondary hyperparathyroidism rapidly develops
symptomatic bone disease, for example, serious
fractures, I would proceed to parathyroid surgery.
On occasion, patients have developed calciphylaxis
with progressive ischemic necrosis of the fingertips,
toes, and elsewhere [99]. This syndrome occurs in
dialysis patients or in renal transplant recipients
with normal renal function. The disease often pro-
gresses rapidly, and patients can die as a con-
sequence: given the observation that some of these
patients improve dramatically following para-
thyroid surgery, surgery should be performed with
haste. One also should consider parathyroidectomy
in uremic patients with extensive soft tissue calcifi-
cation when the hyperphosphatemia has been total-
ly resistant to attempts to deplete phosphate stores.
Serum phosphorus usually decreases transiently af-
ter surgery; then one must convince these patients
to follow rigorous measures for phosphate restric-
tion. Persistent hypercalcemia after successful re-
nal transplantation might be another indication for
surgery, particularly if renal function is deteriorat-
ing.
DR. COHEN: When you do recommend para-
thyroidectomy, do you suggest that the surgeon
perform autotransplantation of the gland?
DR. COBURN: Total parathyroidectomy with au-
totransplantation of parathyroid tissue into the fore-
arm has been recommended to avoid the need for
subsequent neck exploration if hyperparathy-
roidism recurs, and to have the parathyroid tissue in
a more accessible place should removal of more
parathyroid tissue be necessary. Our parathyroid
surgeon prefers not to perform the additional sur-
gery; he rapidly freezes and stores the parathyroid
tissue for subcutaneous implantation should evi-
dence of persistent hypoparathyroidism appear.
The internist or nephrologist involved should work
closely with an experienced parathyroid surgeon to
determine the best procedures to follow in patients
who undergo parathyroid surgery.
DR. KASSIRER: With new hormonal insights into
the pathogenesis of divalent cation and anion distur-
bances in uremia, do you have new insights into ter-
tiarv hyperparathyroidism?
DR. COBURN: This is a term that I prefer not to
use because most data indicate that in most patients
with uremia, serum iPTH levels will decrease when
the blood calcium level is raised; thus, there is no
evidence for autonomy of parathyroid function.
One study has shown that one can produce per-
sistent hypercalcemia in rats by transplanting the
parathyroid gland from 40 normal rats into the sub-
cutaneous tissues [100]. Hypercalcemia does not
necessarily indicate that there is something dif-
ferent about parathyroid cell function. Research in
cows has shown that basal PTH secretion persists
even during marked hypercalcemia [101]. Thus, in-
creased iPTH levels might exist in uremic patients
with mild hypercalcemia on the basis of marked
parathyroid hyperplasia. It would seem better to re-
serve the term "tertiary" hyperparathyroidism for
patients who develop parathyroid adenomas, a rare
occurrence.
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DR. J. T. HARRINGTON: Much has been written
about parathyroid hormone as a uremic toxin. What
are your thoughts about this notion?
DR. COBURN: Data have been reported that sug-
gest that PTH is a pathogenetic factor responsible for
a number of clinical manifestations of uremia. In-
creased calcium content of several soft tissues, in-
cluding skin, blood vessels, and brain, has been re-
ported to be associated with marked secondary hy-
perparathyroidism. The accumulation of calcium in
the brain might be a factor leading to an abnormal
electroencephalogram, particularly in acute uremia;
an increase in calcium content of peripheral nerves
has been reported but there is disagreement. I al-
ready mentioned the occurrence of soft tissue ne-
crosis or calciphylaxis; hyperlipidemia has been at-
tributed in part to high levels of PTH; and anemia
has been associated with secondary hyper-
parathyroidism. Whether the anemia is caused by a
toxic effect of PTH, to marrow fibrosis from osteitis
fibrosa, or to some other factor is uncertain. There
are anecdotal experiences of an increase in libido
and reversal of impotence following a decrease in
PTH levels. However, controlled studies have not
been done. It has been thought that the abnormal
carbohydrate metabolism present in uremia might
be related to high PTH levels. The evidence sup-
porting the role of PTH in these conditions has only
recently begun to accumulate, and this is an area
that we will view with interest.
DR. COHEN: Is there a role for measuring ionized
calcium as opposed to total calcium levels in pa-
tients with renal failure?
DR. COBURN: Unfortunately, few data are avail-
able. With the development of effective, specific ion
electrodes for measuring calcium, some laborato-
ries can now measure the ionized calcium readily.
Uremia is a condition that can be associated with an
increase in the complexed fraction of calcium, so
there might be a decrease in ionized calcium level
for any level of total blood calcium. Further investi-
gation is needed to pursue this question.
Reprint requests to Dr. Jack W. Coburn, Nephrology Section,
VA Wadsworth Medical Center, Wilshire and Sawtelle Boule-
vards, Los Angeles, California 90073.
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